A Phase 1 Study to Evaluate the Safety of KLN-1010, a Novel, In Vivo Gene Therapy to Generate Anti-B Cell Maturation Antigen (Anti-BCMA) Chimeric Antigen Receptor-T Cells (CAR-T) in Patients With Relapsed and Refractory Multiple Myeloma
Latest Information Update: 30 Jul 2025
At a glance
- Drugs KLN 1010 (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions
- Sponsors Kelonia Therapeutics
Most Recent Events
- 30 Jul 2025 New trial record